| Literature DB >> 34944913 |
Angelos P Kassianos1,2, Alexandros Georgiou3, Maria Kyprianidou1, Demetris Lamnisos4, Jeļena Ļubenko5, Giovambattista Presti6, Valeria Squatrito6, Marios Constantinou7, Christiana Nicolaou8, Savvas Papacostas9, Gökçen Aydin10, Yuen Yu Chong11, Wai Tong Chien11, Ho Yu Cheng11, Francisco J Ruiz12, Maria B Garcia-Martin12, Diana Obando12, Miguel A Segura-Vargas12, Vasilis S Vasiliou13, Louise McHugh14, Stefan Höfer15, Adriana Baban16, David Dias Neto17,18, Ana Nunes da Silva19, Jean-Louis Monestès20, Javier Alvarez-Galvez21, Marisa Paez Blarrina22, Francisco Montesinos22,23, Sonsoles Valdivia Salas24, Dorottya Őri25,26, Bartosz Kleszcz27, Raimo Lappalainen28, Iva Ivanović29, David Gosar30, Frederick Dionne31, Rhonda M Merwin32, Andreas Chatzittofis33, Evangelia Konstantinou3, Sofia Economidou3, Andrew T Gloster34, Maria Karekla1, Anastasia Constantinidou3,33,35.
Abstract
A population-based cross-sectional study was conducted during the first COVID-19 wave, to examine the impact of COVID-19 on mental health using an anonymous online survey, enrolling 9565 individuals in 78 countries. The current sub-study examined the impact of the pandemic and the associated lockdown measures on the mental health, and protective behaviors of cancer patients in comparison to non-cancer participants. Furthermore, 264 participants from 30 different countries reported being cancer patients. The median age was 51.5 years, 79.9% were female, and 28% had breast cancer. Cancer participants reported higher self-efficacy to follow recommended national guidelines regarding COVID-19 protective behaviors compared to non-cancer participants (p < 0.01). They were less stressed (p < 0.01), more psychologically flexible (p < 0.01), and had higher levels of positive affect compared to non-cancer participants. Amongst cancer participants, the majority (80.3%) reported COVID-19, not their cancer, as their priority during the first wave of the pandemic and females reported higher levels of stress compared to males. In conclusion, cancer participants appeared to have handled the unpredictable nature of the first wave of the pandemic efficiently, with a positive attitude towards an unknown and otherwise frightening situation. Larger, cancer population specific and longitudinal studies are warranted to ensure adequate medical and psychological care for cancer patients.Entities:
Keywords: COVID-19; cancer patients; health behaviors; mental health; protection behaviors
Year: 2021 PMID: 34944913 PMCID: PMC8699048 DOI: 10.3390/cancers13246294
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Socio-demographic and medical characteristics of the participants who were recruited in the study overall and separately for cancer and non-cancer participants.
| Total | Cancer | Non-Cancer | Effect Size | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Age median | 34 (24–46) | 51.5 (40,60) | 34 (26,45) | 0.15 g | 1.05 i | |
| Gender ( | Male | 2101 (22.0) | 52 (19.7) | 2049 (22.0) | 0.66 h | 0.01 j |
| Female | 7431 (77.7) | 211 (79.9) | 7220 (77.6) | |||
| Other/Non-Binary | 33 (0.3) | 1 (0.4) | 32 (0.3) | |||
| Employment status | Working full time | 5108 (53.4) | 134 (50.8) | 4974 (53.5) | <0.01 h** | 0.15 j |
| Working part time | 1674 (17.5) | 49 (18.6) | 1625 (17.5) | |||
| Unemployed | 2218 (23.2) | 24 (9.1) | 2194 (23.6) | |||
| On parental leave | 241 (2.2) | 6 (2.3) | 208 (2.2) | |||
| Retired | 351 (3.7) | 51 (19.3) | 300 (2.2) | |||
| Working as a health professional ( | Yes | 1556 (16.6) | 54 (21.3) | 1502 (16.5) | 0.33 h | 0.02 j |
| No | 7819 (83.4) | 200 (78.7) | 7619 (83.5) | |||
| University student | Yes | 2718 (28.8) | 26 (10.1) | 2692 (29.3) | 0.04 h* | 0.07 j |
| No | 6735 (71.2) | 232 (89.9) | 6503 (70.7) | |||
| Education level ( | Primary | 77 (0.8) | 2 (0.8) | 75 (0.8) | 0.74 h | 0.04 j |
| Secondary | 2348 (25.2) | 49 (18.6) | 2299 (24.3) | |||
| Higher | 6887 (74.0) | 213 (80.6) | 7097 (74.9) | |||
| Marital status ( | Single | 2947 (31.2) | 48 (18.3) | 2899 (31.6) | 0.88 h | 0.09 j |
| In a relationship/Engaged/Married | 5912 (62.6) | 178 (68.3) | 5734 (62.5) | |||
| Divorced/Widower | 581 (6.2) | 35 (13.4) | 546 (5.9) | |||
| Have children ( | Yes | 3899 (40.8) | 174 (65.9) | 3725 (40.1) | 0.24 h | 0.09 j |
| No | 5666 (59.2) | 90 (34.1) | 5576 (59.9) | |||
| Living situation ( | Live alone | 1397 (14.6) | 47 (17.8) | 1350 (14.5) | 0.45 h | 0.07 j |
| Live with parents | 1991 (20.8) | 19 (7.2) | 1972 (21.2) | |||
| Live with one of parents | 484 (5.1) | 5 (1.9) | 479 (5.2) | |||
| Live with own family | 5171 (54.1) | 185 (70.1) | 4986 (53.6) | |||
| Live with friends/roommates | 522 (5.5) | 8 (3.0) | 514 (5.5) | |||
|
| ||||||
| Infected by COVID-19 ( | Yes | 135 (1.4) | 6 (2.3) | 129 (1.4) | 0.48 h | 0.01 j |
| No | 8417 (88.0) | 230 (87.1) | 8187 (88.0) | |||
| Unsure or have had symptoms but not diagnosed | 1013 (10.6) | 28 (10.6) | 985 (10.6) | |||
| Partner been infected by COVID-19 ( | Yes | 70 (0.7) | 4 (1.5) | 66 (0.7) | 0.27 h | 0.02 j |
| No | 8732 (92.2) | 243 (92.4) | 8489 (92.2) | |||
| Unsure or (s)he has had symptoms but not diagnosed | 670 (7.1) | 16 (6.1) | 654 (7.1) | |||
| Others infected by COVID-19 ( | Yes | 538 (5.6) | 19 (7.2) | 519 (5.6) | 0.38 h | 0.01 j |
| No | 8227 (86.0) | 227 (86.0) | 8000 (86.0) | |||
| Unsure or (s)he has had symptoms but not diagnosed | 799 (8.4) | 18 (6.8) | 781 (8.4) | |||
Abbreviations: IQR, interquartile range; a n = 9563; b n = 9565; c n = 9375; d n = 9453; e n = 9564; f n = 9472; g differences between cancer participants and participants not reporting cancer were examined with t-test if outcomes were continuous variables with normal distributions; h differences between cancer participants and participants not reporting cancer were examined with χ2 test if categorical outcomes; i effect sizes were examined with Cohen’s d if outcomes were continuous variables; j effect sizes were examined with Cramér’s V if outcomes were categorical variables. * Statistically significant p < 0.05 ** Statistically significant p < 0.01.
Comparisons between participants reporting cancer vs. no cancer.
| Total | Cancer | Non-Cancer | Effect Size | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Keeping distance from other people when going out (median (IQR)) a | 9 (8, 10) | 10 (9–10) | 9 (8–10) | <0.01 c* | 0.19 e | |
| Self-isolating, limiting unnecessary travelling according to national guidelines (median (IQR)) a | 10 (9, 10) | 10 (9–10) | 10 (9–10) | 0.05 c* | 0.03 e | |
| Washing hands regularly with water and soap (median (IQR)) a | 10 (9, 10) | 10 (9–10) | 10 (9–10) | 0.04 c* | 0.17 e | |
| Protective behaviors self-efficacy (median (IQR)) | 6.2 (5.6–7) | 6.6 (5.9–7) | 6.2 (5.6–7) | <0.01 c** | 0.20 e | |
|
| ||||||
| Social support (OSS)e (Ν (%)) b | Low | 2337 (24.4) | 52 (19.8) | 2285 (24.6) | <0.01 d** | 0.03 f |
| Moderate | 4999 (52.3) | 129 (49.0) | 4870 (52.4) | |||
| High | 2227 (23.3) | 82 (31.2) | 2145 (23.0) | |||
| Family functioning (BAFFS) (median (IQR)) | 6 (4–7) | 5 (4–6) | 6 (4–7) | 0.45 c | 0.10 e | |
|
| ||||||
| Perceived stress (PSS) (median (IQR)) | 17 (12–22) | 15 (10–20) | 17 (12–22) | <0.01 c** | 0.27 e | |
| Levels of perceived stress (Ν (%)) b | Low | 3159 (33.0) | 119 (45.3) | 3040 (32.7) | <0.01 d** | 0.04 f |
| Moderate | 5344 (55.9) | 120 (45.6) | 5224 (56.2) | |||
| High | 1060 (11.1) | 24 (9.1) | 1036 (11.1) | |||
| Psychological flexibility (Psy-Flex) (median (IQR)) | 34 (30, 37) | 35 (32, 38) | 34 (30, 37) | <0.01 c** | 0.37 e | |
| Mindfulness (CAMS) (median (IQR)) | 27 (24–29) | 27 (25–30) | 27 (24–29) | 0.04 c* | 0.19 e | |
| Prosocialness (PSA) (median (IQR)) | 23 (20, 26) | 23 (20–26) | 23 (20–26) | 0.99 c | 0.01 e | |
| Depressive symptomatology (MSBS—reinforcement) (median (IQR)) | 3 (3–3) | 3 (3–3) | 3 (2,3) | 0.77 c | 0.10 e | |
| Depressive symptomatology (MSBS -boredom) (median (IQR)) | 2 (1.5–3) | 2 (1.5–2.5) | 2 (1.5–3) | <0.01 c** | 0.24 e | |
| Wellbeing total (MHCSF) (median (IQR)) | 42 (31–52) | 46 (36–54) | 42 (31–52) | <0.01 c** | 0.22 e | |
| Hedonic wellbeing (MHCSF) (median (IQR)) | 11 (8–12) | 12 (9–13) | 11 (8–12) | <0.01 c** | 0.19 e | |
| Eudemonic social wellbeing (MHCSF) (median (IQR)) | 11 (7–16) | 12 (8–17) | 11 (7–16) | 0.21 c | 0.16 e | |
| Eudemonic psychological wellbeing (MHCSF) (median (IQR)) | 21 (15–24) | 23 (18–26) | 21 (15–24) | <0.01 c** | 0.24 e | |
| Wellbeing type (MHCSF) | Languishing | 882 (10.1) | 20 (8.1) | 862 (10.2) | <0.01 d** | 0.04 f |
| Moderately mentally healthy | 4345 (50.0) | 104 (41.9) | 4241 (50.2) | |||
| Flourishing | 3468 (39.9) | 124 (50.0) | 3344 (39.6) | |||
| Positive affect (PANAS) (median (IQR)) | 29 (23–35) | 30 (25–37) | 29 (23–35) | 0.01 c* | 0.21 e | |
| Negative affect (PANAS) (median (IQR)) | 28 (21–38) | 26 (20–33) | 28 (21–38) | 0.01 c* | 0.19 e | |
|
| ||||||
| Perceived susceptibility (median (IQR)) | 9 (6–11) | 11 (7.5, 14) | 8 (6–11) | <0.01 c** | 0.56 e | |
| Perceived severity (median (IQR)) | 13 (10–15) | 14 (12–17) | 13 (10–15) | <0.01 c** | 0.37 e | |
Abbreviations: BAFFS = Brief Assessment for Family Functioning Scale; CAMS = Cognitive and Affective Mindfulness Scale; IQR = interquartile range; MHCSF = Mental Health Continuum Short Form; MSBS = Multidimensional State Boredom Scale; OSS = Oslo Social Supports Scale; PANAS = Positive and Negative Affect Scale; PSA = Prosocialness Scale for Adults; PSS = Perceived Stress Scale; a Ν = 9565; b N = 9563 c differences between cancer and non-cancer participants were examined with χ2 test; d differences between cancer and non-cancer participants were examined with Kolmogorov–Smirnov test; e effect size between cancer and non-cancer participants was examined with Cohen’s d; f effect size between cancer and non-cancer participants was examined with Cramér’s V. * Statistically significant p < 0.05 ** Statistically significant p < 0.01.
Multivariate linear regression of the level of keeping distance as a linear combination of social support (model 1), perceived susceptibility and perceived severity (model 2), change in finances during quarantine and availability of obtaining all the basic supplies (model 3), psychological flexibility (model 4), and all the predictors (model 5) after adjusting for different socio-demographic and socio-economic characteristics (i.e., age, gender).
| Coefficient | |||||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
|
| |||||
| Cancer | Ref | Ref | Ref | Ref | Ref |
| COVID-19 | 0.57 (0.07, 1.07) * | 0.29 (−0.23, 0.80) | 0.63 (0.13, 1.14) * | 0.62 (0.12, 1.11) * | 0.43 (−0.09, 0.94) |
|
| 0.01 (−0.01, 0.02) | 0.00 (−0.02, 0.02) | 0.01 (−0.01, 0.02) | 0.00 (−0.02, 0.02) | −0.01 (−0.02, 0.01) |
|
| |||||
| Male | Ref | Ref | Ref | Ref | Ref |
| Female | −0.11 (−0.78, 0.56) | −0.17 (−0.87, 0.46) | −0.02 (−0.71, 0.67) | −0.18 (−0.85, 0.48) | −0.18 (−0.86, 0.49) |
|
| |||||
| Thyroid | Ref | Ref | Ref | Ref | Ref |
| GI | 0.31 (−0.71, 1.33) | 0.11 (−0.89, 1.10) | 0.42 (−0.60, 1.44) | 0.41 (−0.59, 1.42) | 0.33 (−0.66, 1.32) |
| Breast | 0.33 (−0.45, 1.11) | 0.38 (−0.41, 1.10) | 0.43 (−0.35, 1.22) | 0.38 (−0.38, 1.15) | 0.48 (−0.27, 1.23) |
| Soft molecular | −0.84 (−3.97, 2.29) | −0.56 (−3.51, 2.57) | −0.83 (−3.95, 2.29) | −0.69 (−3.76, 2.39) | −0.28 (−3.28, 2.72) |
| Female reproductive | 0.43 (−0.47, 1.33) | 0.34 (−0.54, 1.21) | 0.56 (−0.35, 1.47) | 0.43 (−0.45, 1.32) | 0.49 (−0.38, 1.36) |
| Leukemia | 0.29 (−0.72, 1.30) | 0.30 (−0.67, 1.29) | 0.43 (−0.60, 1.46) | 0.26 (−0.73, 1.25) | 0.43 (−0.56, 1.42) |
| Lymphoma | 0.19 (−0.85, 1.24) | 0.08 (−0.98, 1.05) | 0.25 (−0.79, 1.29) | 0.32 (−0.71, 1.34) | 0.16 (−0.84, 1.17) |
| Cervical | 0.01 (−1.70, 1.71) | −0.20 (−1.89, 1.42) | 0.14 (−1.56, 1.85) | −0.09 (−1.77, 1.59) | −0.18 (−1.82, 1.47) |
| Skin | 0.25 (−0.69, 1.18) | 0.24 (−0.67, 1.14) | 0.34 (−0.59, 1.28) | 0.22 (−0.69, 1.14) | 0.32 (−0.58, 1.21) |
| Lung | 1.06 (−0.88, 3.00) | 1.35 (−0.70, 3.06) | 1.24 (−0.69, 3.16) | 1.18 (−0.71, 3.07) | 1.28 (−0.58, 3.13) |
| Urine | 0.34 (−0.99, 1.66) | 0.23 (−0.97, 1.59) | 0.37 (−0.96, 1.69) | 0.50 (−0.80, 1.80) | 0.57 (−0.71, 1.85) |
| Testicular | 0.53 (−1.49, 2.54) | 0.33 (−1.62, 2.32) | 0.52 (−1.49, 2.53) | 0.04 (−1.97, 2.04) | −0.01 (−1.96, 1.96) |
| Prostate | 0.57 (−0.83, 1.98) | 0.87 (−0.59, 2.15) | 0.82 (−0.60, 2.24) | 0.54 (−0.83, 1.91) | 0.92 (−0.46, 2.30) |
| Bone | 0.22 (−1.45, 1.90) | 0.50 (−1.18, 2.08) | 0.26 (−1.41, 1.92) | 0.16 (−1.48, 1.80) | 0.34 (−1.26, 1.95) |
| Brain | 0.13 (−1.53, 1.80) | 0.42 (−1.13, 2.12) | 0.10 (−1.56, 1.76) | 0.17 (−1.46, 1.81) | 0.54 (−1.06, 2.14) |
|
| |||||
| Yes | Ref | Ref | Ref | Ref | Ref |
| No | −0.39 (−0.90, 0.12) | −0.31 (−0.81, 0.19) | −0.46 (−0.97, 0.05) | −0.39 (−0.89, 0.10) | −0.38 (−0.88, 0.11) |
|
| 0.05 (−0.04, 0.14) | 0.03 (−0.06, 0.12) | |||
|
| |||||
| Perceived susceptibility | −0.08 (−0.14, −0.01) * | −0.07 (−0.13, −0.01) * | |||
| Perceived severity | 0.15 (0.07, 0.23) * | 0.14 (0.06, 0.22) * | |||
|
| |||||
| Have got better | Ref | Ref | |||
| Stayed the same | 1.12 (0.03, 2.21) * | 1.18 (0.13, 2.23) * | |||
| Have got worse | 1.25 (0.13, 2.38) * | 1.36 (0.27, 2.45) * | |||
|
| |||||
| Yes | Ref | Ref | |||
| No | −0.20 (−1.08, 0.67) | −0.13 (−0.97, 0.72) | |||
|
| 0.06 (0.02, 0.10) * | 0.05 (0.01, 0.09) * | |||
Note: * Statistically significant p < 0.05.
Multivariate linear regression of stress as a linear combination of social support (model 1), perceived susceptibility and perceived severity (model 2), change in finances during quarantine and availability of obtaining all the basic supplies (model 3), psychological flexibility (model 4), and all the predictors (model 5) after adjusting for different socio-demographic and socio-economic characteristics (i.e., age, gender).
| Coefficient ( | |||||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
|
| |||||
| Cancer | Ref | Ref | Ref | Ref | Ref |
| COVID-19 | 0.73 (−1.50, 2.97) | 0.66 (−1.69, 2.92) | 0.97 (−1.22, 3.17) | 0.38 (−1.71, 2.46) | 0.29 (−1.82, 2.41) |
|
| −0.16 (−0.24, −0.08) * | −0.12 (−1.20, −0.04) * | −0.15 (−0.23, −0.08) * | −0.10 (−0.18, −0.03) * | −0.07 (−0.14, 0.01) |
|
| |||||
| Male | Ref | Ref | Ref | Ref | Ref |
| Female | 0.53 (−2.46, 3.52) | 1.49 (−1.51, 4.50) | 1.41 (−1.59, 4.41) | 1.16 (−1.63, 3.95) | 3.01 (0.24, 5.78) * |
|
| |||||
| Thyroid | Ref | Ref | Ref | Ref | Ref |
| GI | −1.03 (−5.57, 3.50) | −1.27 (−5.77, 3.22) | −0.33 (−4.79, 4.12) | −2.00 (−6.23, 2.22) * | −1.48 (−5.56, 2.60) * |
| Breast | −3.99 (−7.45, −0.53) * | −4.40 (−7.81, −1.00) * | −3.80 (−7.20, −0.40) * | −4.43 (−7.65, −1.21) * | −4.32 (−7.40, −1.24) * |
| Soft molecular | −13.12 (−27.03, 0.79) | −13.99 (−27.70, −0.27) * | −11.05 (−24.64, 2.54) | −14.45 (−27.40, −1.50) * | −14.21 (−26.54, −1.88) * |
| Female reproductive | −4.70 (−8.68, −0.67) * | −4.67 (−8.62, −0.72) * | −4.47 (−8.41, −0.52) * | −4.71 (−8.43, −0.98) * | −4.68 (−8.25, −1.10) * |
| Leukemia | −5.60 (−10.07, −1.12) * | −6.25 (−10.66, −1.83) * | −5.95 (−10.41, −1.48) * | −5.35 (−9.52, −1.19) * | −6.39 (−10.45, −2.33) * |
| Lymphoma | −7.52 (−12.16, −2.90) * | −7.85 (−12.42, −3.28) * | −7.56 (−12.10, −3.03) * | −8.76 (−13.07, 4.45) | −8.11 (−12.25, −3.98) * |
| Cervical | −8.10 (−15.67, −0.52) * | −7.40 (−14.87, 0.07) | −9.03 (−16.47, −1.59) * | −7.21 (−14.27, −0.16) * | −7.46 (−14.21, −0.70) * |
| Skin | −6.62 (−10.77, −2.48) * | −6.40 (−10.47, −2.32) * | −6.65 (−10.71, −2.59) * | −6.43 (−10.29, −2.57) * | −6.36 (−10.04, −2.68) * |
| Lung | −5.95 (−14.56, 2.66) | −7.70 (−16.12, 0.73) | −8.08 (−16.46, 0.30) | −7.19 (−15.15, 0.77) | −7.72 (−15.36, −0.09) * |
| Urine | −0.88 (−6.74, 4.98) | −0.05 (−5.80, 5.69) | 1.37 (−4.38, 7.12) | −2.26 (−7.73, 3.21) | −0.69 (−5.94, 4.57) |
| Testicular | −13.54 (−22.49, −4.59) * | −10.95 (−19.84, −2.05) * | −13.09 (−21.83, −4.35) * | −9.10 (−17.50, −0.62) * | −7.83 (−15.90, 0.24) |
| Prostate | −6.16 (−12.38, 0.07) | −5.97 (−12.15, 0.20) | −5.10 (−11.29, 1.09) | −5.90 (−11.68, −0.12) * | −3.64 (−9.30, 2.03) |
| Bone | 1.36 (−6.06, 8.79) | −0.21 (−7.54, 7.11) | 0.47 (−6.79, 7.73) | 1.91 (−5.01, 8.82) | 0.63 (−5.97, 7.23) |
| Brain | 0.53 (−6.87, 7.93) | 0.17 (−7.15, 7.48) | 1.99 (−5.24, 9.22) | 0.25 (−6.64, 7.13) | 0.27 (−6.32, 6.86) |
|
| |||||
| Yes | Ref | Ref | Ref | Ref | Ref |
| No | −1.00 (−3.26, 1.25) | −0.49 (−2.75, 1.77) | −1.05 (−3.27, 1.17) | −0.94 (−3.05, 1.16) | −0.58 (−2.62, 1.46) |
|
| −0.57 (−0.96, −0.17) * | −0.18 (−0.56, 0.19) | |||
|
| |||||
| Perceived susceptibility | 0.57 (0.28, 0.86) * | 0.42 (0.15, 0.68) * | |||
| Perceived severity | −0.26 (−0.62, 0.10) | −0.18 (−0.51, 0.15) | |||
|
| |||||
| Have got better | Ref | Ref | |||
| Stayed the same | −0.18 (−4.93, 4.56) | −1.40 (−5.70, 2.91) | |||
| Have got worse | 3.49 (−1.41, 8.38) | 1.73 (−2.73, 6.20) | |||
|
| |||||
| Yes | Ref | Ref | |||
| No | 5.69 (1.88, 9.50) * | 4.97 (1.49, 8.44) * | |||
|
| −0.54 (−0.71, −0.38) * | −0.42 (−0.60, −0.25) * | |||
Note: * Statistically significant p < 0.05.
Comparisons between cancer participants who had cancer as their priority vs. those who had COVID-19 as their priority.
| Cancer Priority ( | COVID-19 Priority ( | Effect Size | |||
|---|---|---|---|---|---|
|
| |||||
| Median age of participants (years (IQR)) a | 54.5 (44, 57.5) | 50 (39, 60) | 0.15 m | 0.07 n | |
| Gender ( | Males | 12 (23.1) | 35 (18.3) | 0.66 k | 0.06 o |
| Females | 40 (76.9) | 155 (81.2) | |||
| Other/Non-Binary | 0 (0.0) | 1 (0.5) | |||
| Employment status ( | Working full time | 134 (50.8) | 4974 (53.5) | <0.01 k** | 0.15 o |
| Working part time | 49 (18.6) | 1625 (17.5) | |||
| Unemployed | 24 (9.1) | 2194 (23.6) | |||
| On parental leave | 6 (2.3) | 208 (2.2) | |||
| Retired | 51 (19.3) | 300 (2.2) | |||
| Working as a health professional ( | Yes | 13 (26.0) | 36 (19.7) | 0.33 k | 0.06 o |
| No | 37 (74.0) | 147 (80.3) | |||
| University student ( | Yes | 1 (2.0) | 22 (11.8) | 0.04 k* | 0.14 o |
| No | 50 (98.0) | 164 (88.2) | |||
| Education level ( | Primary | 0 (0.0) | 2 (1.1) | 0.74 k | 0.09 o |
| Secondary | 9 (17.3) | 34 (18.2) | |||
| Higher | 43 (82.7) | 151 (80.7) | |||
| Marital status ( | Single | 10 (19.6) | 34 (18.0) | 0.88 k | 0.10 o |
| In a relationship/Engaged/Married | 35 (68.6) | 128 (67.7) | |||
| Divorced/Widower | 6 (11.8) | 27 (14.3) | |||
| Having children ( | Yes | 37 (71.2) | 119 (62.3) | 0.24 k | 0.08 o |
| No | 15 (28.8) | 72 (37.7) | |||
| Living situation ( | Living alone | 7 (13.5) | 38 (19.9) | 0.45 k | 0.12 o |
| Living with parents | 5 (9.6) | 14 (7.3) | |||
| Living with one of parents | 2 (3.9) | 3 (1.6) | |||
| Living with own family | 38 (73.1) | 131 (68.6) | |||
| Living with friends/roommates | 0 (0.0) | 5 (2.6) | |||
| Type of cancer ( | Breast cancer | 19 (36.5) | 47 (25.7) | 0.67 | 0.23 o |
| Female reproductive system cancers | 3 (5.8) | 24 (13.1) | |||
| Cervical cancers | 0 (0.0) | 4 (22) | |||
| Thyroid cancer | 4 (7.7) | 19 (10.4) | |||
| GI cancer | 7 (13.5) | 10(5.5) | |||
| Leukemia and blood cancers | 3 (5.8) | 14 (7.7) | |||
| Lymphomas | 4 (7.7) | 13 (7.1) | |||
| Testicular cancers | 0 (0.0) | 3 (1.6) | |||
| Lung cancers | 3 (5.8) | 5 (2.7) | |||
| Skin cancers | 4 (7.7) | 21 (11.5) | |||
| Brain cancers | 1 (1.9) | 3 (1.6) | |||
| Prostate cancers | 2 (3.8) | 8 (4.4) | |||
| Bone cancers | 0 (0.0) | 4 (2.2) | |||
| Urine cancers | 2 (3.8) | 6 (3.3) | |||
| Soft molecular cancers | 0 (0.0) | 2 (1.1) | |||
| In therapy ( | Yes | 15 (28.8) | 40 (20.9) | 0.23 k | 0.08 o |
| No | 37 (71.2) | 151 (79.1) | |||
| Type of therapy ( | Adjuvant preventative | 12 (70.6) | 31 (73.8) | 0.80 k | 0.20 o |
| For active disease | 5 (29.4) | 11 (26.2) | |||
| The scariest thing at this moment? ( | Cancer | 44 (89.8) | 37 (19.9) | <0.01 k** | 0.60 o |
| COVID-19 | 5 (10.2) | 149 (80.1) | |||
| The most harmful thing at this moment? ( | Cancer | 43 (84.3) | 28 (14.8) | <0.01 k** | 0.62 o |
| COVID-19 | 8 (15.7) | 161 (85.2) | |||
|
| |||||
| Keeping distance from other people when going out (median (IQR)) a | 10 (8.5–10) | 10 (9–10) | 0.77 l | 0.28 n | |
| Self-isolating, limiting unnecessary travelling according to national guidelines (median (IQR)) a | 10 (9–10) | 10 (9–10) | 0.16 l | 0.38 n | |
| Washing hands regularly with water and soap (median (IQR)) a | 10 (9–10) | 10 (9–10) | 0.99 l | 0.20 n | |
|
| |||||
| Social support (OSS) j ( | Low | 9 (17.3) | 43 (22.6) | 0.70 k | 0.05 o |
| Moderate | 25 (48.1) | 88 (46.3) | |||
| High | 18 (34.6) | 59 (31.1) | |||
|
| |||||
| Scoree ( | Low | 24 (46.1) | 81 (42.6) | 0.58 k | 0.07 o |
| Moderate | 25 (48.1) | 89 (46.8) | |||
| High | 3 (5.8) | 20 (10.6) | |||
|
| |||||
| Perceived susceptibility (median (IQR)) | 9.5 (6.5–13) | 11 (8–14) | 0.34 g | 0.28 n | |
| Perceived severity (median (IQR)) | 12.5 (9–15) | 15 (13–17) | <0.01 g** | 0.74 n | |
Abbreviations: SD = standard deviation; IQR = interquartile range; OSS = Oslo Social Support Scale; PSS = Perceived Stress Scale a n = 264; b n = 254; c n = 258; d n = 260; e n = 261; f n = 235; g n = 145; h n = 242; i n = 244; j n = 263; k differences between cancer priority and COVID priority were evaluated by the chi-square test. l Differences between cancer priority and COVID priority were evaluated by the Kolmogorov–Smirnov test. m differences between cancer priority and COVID priority were evaluated by the t-test; n effect size between males and females was examined with Cohen’s d; o effect size between males and females was examined with Cramér’s V. * Statistically significant p < 0.05 ** Statistically significant p < 0.01.